drugset
drugset / Trial / NCT05662397

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

NCT05662397 ↗

Phase 1/2 Active not recruiting 77 enrolled HotSpot Therapeutics, Inc
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of care.

Timeline

Start
2023-03-15
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HST-1011 Unknown — Oral
Background Cemiplimab Monoclonal antibody — Intravenous

Indications

cancer